Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region

Until recently, international and Asia‐specific guidelines for advanced urothelial carcinoma (UC) recommended first‐line (1L) platinum‐based chemotherapy, followed by second‐line (2L) anti‐PD‐1 or anti‐PD‐L1 immune checkpoint inhibitor (ICI) therapy where possible, or 1L ICI therapy in cisplatin‐ineligible patients with PD‐L1+ tumors. However, long‐term outcomes remain poor and only a minority of patients receive 2L therapy. The JAVELIN Bladder 100 trial—which assessed avelumab (anti‐PD‐L1 antibody) as 1L maintenance therapy plus best supportive care (BSC) versus BSC alone in patients with advanced UC that had not progressed with 1L platinum‐based chemotherapy—is the only phase 3 trial of ICI‐based treatment in the 1L setting to show significantly improved overall survival, and this treatment approach is now recommended in updated treatment guidelines. Available data from the trial suggest that efficacy and safety in patients enrolled in the Asia‐Pacific region were similar to findings in the overall population. In this review, we discuss the treatment of advanced UC, with a specific focus on studies in the Asia‐Pacific region, and summarize key findings supporting the use of avelumab 1L maintenance as a standard of care in this setting both in cisplatin‐eligible and cisplatin‐ineligible patients and irrespective of PD‐L1 status.

[1]  A. Ravaud,et al.  BLADDER CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Galsky,et al.  Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130 , 2021, Clinical Trials.

[3]  M. Galsky,et al.  Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130 , 2021, Clinical Trials.

[4]  T. Powles,et al.  Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[5]  Craig B. Davis,et al.  Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial. , 2021 .

[6]  T. Powles,et al.  Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance. , 2021 .

[7]  N. Agarwal,et al.  Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. , 2021, Cancer treatment reviews.

[8]  M. Galsky,et al.  A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE). , 2021 .

[9]  T. Powles,et al.  Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. , 2021 .

[10]  T. Powles,et al.  Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis. , 2021 .

[11]  T. Powles,et al.  1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361. , 2021 .

[12]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[13]  N. Agarwal,et al.  Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. , 2021, Cancer treatment and research communications.

[14]  L. Kiemeney,et al.  Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. , 2020, Cancer treatment and research communications.

[15]  T. Powles,et al.  Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. , 2020, The Lancet. Oncology.

[16]  Craig B. Davis,et al.  Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. , 2020, The New England journal of medicine.

[17]  T. Powles,et al.  798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer , 2020 .

[18]  C. Tournigand,et al.  745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC) , 2020 .

[19]  [Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China]. , 2020, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[20]  T. Tsuzuki,et al.  Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision , 2020, International journal of urology : official journal of the Japanese Urological Association.

[21]  T. Powles,et al.  Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Galsky,et al.  Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[23]  J. Pérez-Gracia,et al.  Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. , 2020, Clinical genitourinary cancer.

[24]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[25]  M. Galsky,et al.  Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Joseph,et al.  Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre , 2020, Frontiers in Oncology.

[27]  Motonobu Nakamura,et al.  Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma , 2020, Oncology letters.

[28]  L. Kiemeney,et al.  The global burden of urinary bladder cancer: an update , 2019, World Journal of Urology.

[29]  B. Monk,et al.  Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State , 2019, Targeted Oncology.

[30]  S. Thongprasert,et al.  Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough? , 2019, ESMO Open.

[31]  J. Simeone,et al.  Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting. , 2019, Cancer epidemiology.

[32]  N. Robert,et al.  Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. , 2019, Future oncology.

[33]  A. Hussain,et al.  Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma , 2019, Journal of medical economics.

[34]  Y. Nishimura,et al.  Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer , 2019, AntiCancer Research.

[35]  National Health Commission of PRC.  Chinese guidelines for diagnosis and treatment of urothelial carcinoma of bladder 2018 (English version) , 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[36]  H. Pappot,et al.  Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature , 2019, Health and Quality of Life Outcomes.

[37]  K. Goldberg,et al.  FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy , 2018, The oncologist.

[38]  M. Fenton,et al.  Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008‐2015 , 2018, Clinical genitourinary cancer.

[39]  S. Pang,et al.  Recent advances in upper tract urothelial carcinomas: From bench to clinics , 2018, International journal of urology : official journal of the Japanese Urological Association.

[40]  J. Kaouk,et al.  Feasibility of Cisplatin‐Based Neoadjuvant Chemotherapy in Muscle‐Invasive Bladder Cancer Patients With Diminished Renal Function , 2018, Clinical genitourinary cancer.

[41]  G. Sonpavde,et al.  Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States , 2018, Bladder cancer.

[42]  J. Wolchok,et al.  Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab , 2018, Clinical Cancer Research.

[43]  A. Rudolph,et al.  A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany , 2018, Journal of Cancer.

[44]  S. Culine,et al.  Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  L. Mariani,et al.  Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma , 2018, The Journal of urology.

[46]  T. Powles,et al.  A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901). , 2018 .

[47]  T. Powles,et al.  Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. , 2018, European Urology.

[48]  M. Wong,et al.  The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection , 2018, Scientific Reports.

[49]  A. Gupta,et al.  Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma , 2018, Clinical pharmacology and therapeutics.

[50]  E. Gallardo,et al.  Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[51]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[52]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[53]  L. Mariani,et al.  Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). , 2017, European urology.

[54]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[55]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[56]  C. la Vecchia,et al.  The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. , 2016, European urology.

[57]  H. Kume,et al.  Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world , 2016, World Journal of Urology.

[58]  K. Rau,et al.  The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. , 2015, Urologic oncology.

[59]  Pau-Chung Chen,et al.  Chinese Herbs Containing Aristolochic Acid Associated with Renal Failure and Urothelial Carcinoma: A Review from Epidemiologic Observations to Causal Inference , 2014, BioMed research international.

[60]  G. Sonpavde,et al.  Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. , 2014, Clinical genitourinary cancer.

[61]  David C. Smith,et al.  Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma , 2014, Cancer.

[62]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[63]  S. Matin,et al.  Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high‐volume centre in China , 2013, BJU international.

[64]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[65]  C. Shun,et al.  Aristolochic acid‐induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes , 2013, International journal of cancer.

[66]  G. Sonpavde,et al.  Efficacy of Cisplatin-Based Chemotherapy as First-Line Treatment in Asian Patients with Metastatic Urothelial Carcinoma Results of an Exploratory Subgroup Analysis of a Pool Analysis of Phase II/III Trials , 2012 .

[67]  Arthur P. Grollman,et al.  Aristolochic acid-associated urothelial cancer in Taiwan , 2012, Proceedings of the National Academy of Sciences.

[68]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  G. Sonpavde,et al.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  A. Horwich,et al.  Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[72]  D. Amadori,et al.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.

[73]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[75]  Jin-Hwang Liu,et al.  Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. , 2002, Urology.

[76]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  A. Ravaud,et al.  Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. , 2018, The Lancet. Oncology.

[79]  D. Berney,et al.  Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Guideline on the investigation of subgroups in confirmatory clinical trials , 2014 .